DCAF13通过调节c-Myc表达来通过代谢重编程影响乳腺癌化疗耐药性
Shiqiang Bai1, Yunlong Hu2, Ning Chen1
1Department of Pathology, The 966th Hospital of The PLA Joint Logistic Support Force, Dandong, 118000, China.
Medical oncology (Northwood, London, England)
|April 23, 2025
概括
这项研究揭示了DCAF13作为乳腺癌化学疗法耐药性的关键驱动因素,通过促进c-Myc和改变细胞代谢. 准DCAF13可能会提供克服耐药性的新策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 化疗耐药性是乳腺癌治疗的一个重大挑战.
- 识别药物耐药性的新型调节剂对于改善患者的治疗结果至关重要.
研究的目的:
- 研究DCAF13在乳腺癌中调节化疗耐药性的作用.
- 阐明涉及c-Myc和代谢重编程的潜在机制.
主要方法:
- 对抗性与敏感性乳腺癌细胞系中DCAF13表达的比较分析.
- 功能性研究涉及DCAF13抑制和过度表达.
- 评估c-Myc水平和代谢途径活性 (糖解,氧化酸化).
- 对DCAF13表达与乳腺癌患者临床预后的相关性分析.
主要成果:
- 在耐化疗乳腺癌细胞中,DCAF13的表达被上调.
- 抑制DCAF13恢复了对化疗的敏感性,而过度表达则减少了它.
- DCAF13上调调节c-Myc,导致代谢重编程 (增加糖解和氧化酸化).
- 增加DCAF13表达与预后不佳相关,特别是在晚期和三阴性乳腺癌 (TNBC) 中.
结论:
- 通过代谢重编程,DCAF13-c-Myc轴是乳腺癌中化疗耐药性的关键调解者.
- 准DCAF13通路是一种潜在的治疗策略,可以克服耐药性.
- 进一步对DCAF13作为治疗点进行临床研究是有必要的.
更多相关视频
10:26Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids
Published on: October 21, 2022
1.8K
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.2K
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Induced Pluripotent Stem Cells
3.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.8K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
